Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T23953
(Former ID: TTDR00392)
|
|||||
Target Name |
Prostate stem cell antigen (PSCA)
|
|||||
Synonyms |
UNQ206/PRO232
Click to Show/Hide
|
|||||
Gene Name |
PSCA
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 5 Target-related Diseases | + | ||||
1 | Pancreatic cancer [ICD-11: 2C10] | |||||
2 | Prostate cancer [ICD-11: 2C82] | |||||
3 | Stomach cancer [ICD-11: 2B72] | |||||
4 | Non-small-cell lung cancer [ICD-11: 2C25] | |||||
5 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
Function |
Has a cell-proliferation inhibition activity in vitro. May be involved in the regulation of cell proliferation.
Click to Show/Hide
|
|||||
UniProt ID | ||||||
Sequence |
MAGLALQPGTALLCYSCKAQVSNEDCLQVENCTQLGEQCWTARIRAVGLLTVISKGCSLN
CVDDSQDYYVGKKNITCCDTDLCNASGAHALQPAAAILALLPALGLLLWGPGQL Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
1 | Anti-PSCA mab | Drug Info | Phase 2 | Pancreatic cancer | [2] | |
2 | BPX-601 | Drug Info | Phase 1/2 | Gastric adenocarcinoma | [3] | |
3 | CAR-T Cells targeting PSCA | Drug Info | Phase 1 | Pancreatic cancer | [4] | |
4 | CAR-T cells targeting PSCA | Drug Info | Phase 1 | Solid tumour/cancer | [5] | |
5 | GEM3PSCA | Drug Info | Phase 1 | Non-small-cell lung cancer | [6] | |
6 | MB-105 | Drug Info | Phase 1 | Prostate cancer | [7] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | Anti-PSCA mab | Drug Info | [1] | |||
CAR-T-Cell-Therapy | [+] 3 CAR-T-Cell-Therapy drugs | + | ||||
1 | BPX-601 | Drug Info | [3] | |||
2 | CAR-T Cells targeting PSCA | Drug Info | [4] | |||
3 | CAR-T cells targeting PSCA | Drug Info | [5] | |||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | GEM3PSCA | Drug Info | [8] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Similarity Proteins
Human Tissue Distribution
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71. | |||||
REF 2 | ClinicalTrials.gov (NCT01608711) A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002. U.S. National Institutes of Health. | |||||
REF 3 | ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors | |||||
REF 4 | ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | |||||
REF 5 | ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers | |||||
REF 6 | ClinicalTrials.gov (NCT03927573) Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker. U.S. National Institutes of Health. | |||||
REF 7 | ClinicalTrials.gov (NCT03873805) PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health. | |||||
REF 8 | Clinical pipeline report, company report or official report of Gemoab. | |||||
REF 9 | Clinical pipeline report, company report or official report of Mustang Bio. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.